Comparison of the Efficacy of Filgrastim and an Inactivated Parapoxvirus ovis Paraimmune Activator in Naturally Infected Cats with Feline Panleukopenia [PDF]
AnimalsFeline panleukopenia (FPL) is a serious viral disease caused by Feline panleukopenia virus (FPV) that causes leukopenia, lymphopenia, and neutropenia, particularly in young or unvaccinated cats. There is no specific antiviral treatment available for FPL,
Emre Tüfekçi +9 more
doaj +2 more sources
An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma [PDF]
Scientific ReportsThis study compared efficacy and safety of lipegfilgrastim with filgrastim in pediatric patients. Children and adolescents receiving chemotherapy (4 cycles) for Ewing sarcoma or rhabdomyosarcoma were randomized 1:1 to lipegfilgrastim (100 µg/kg) once per
Margarita B. Belogurova +4 more
doaj +2 more sources
Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study [PDF]
Annals of HematologyIn patients with classical Hodgkin lymphoma (c-HL) undergoing ABVD chemotherapy for advanced disease, the optimal strategy to prevent febrile neutropenia (FN)—defined as fever ≥ 38 °C with absolute neutrophil count (ANC)
Claudia Giordano +11 more
doaj +2 more sources
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities [PDF]
BMC Cancer, 2004 Background Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects.
Moore Kelley +6 more
doaj +4 more sources
Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma [PDF]
Scientific ReportsThis phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or ...
Hideki Goto +17 more
doaj +2 more sources
Biology, 2021 Background: The aim of this review and meta-analysis was to identify, assess, meta-analyze and summarize the comparative effectiveness and safety of filgrastim in head-to-head trials with placebo/no treatment, pegfilgrastim (and biosimilar filgrastim to ...
Shruti Rastogi +5 more
doaj +1 more source
Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
Folia Medica Indonesiana, 2021 Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome.
Reta Anggraeni Widya +3 more
doaj +1 more source
Frontiers in Neurology, 2021 Objective: Developing an integrative approach to early treatment response classification using survival modeling and bioinformatics with various biomarkers for early assessment of filgrastim (granulocyte colony stimulating factor) treatment effects in ...
Siw Johannesen +26 more
doaj +1 more source
Clinical Hematology International, 2019 The biologic medication filgrastim is approved by the Food and Drug Administration (FDA) to mobilize hematopoietic progenitor cells (HPCs) for collection by leukapheresis for autologous hematopoietic stem cell transplant (HSCT). The FDA-approved biologic
Dwight D. Eplin +5 more
doaj +1 more source
Haematologica, 2017 Randomized trials have conclusively shown higher rates of chronic graft-versus-host disease with filgrastim-stimulated apheresis peripheral blood as a donor source than unstimulated bone marrow.
Amina Kariminia +27 more
doaj +1 more source